← Leaderboards
Chandrani Sarkar
Ohio State University
$367,923
Attributed
$367,923
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $203.4K · FY2018–19$250K$187.5K$125K$62.5K$0
'18
'19
Funding mix
By agency
NIH$367,923 · 1
By mechanism
R21$367,923 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Kathleen Marie Dungan$1,325,114
- Bruce S Zwilling$2,803,324
- Kathleen S. Stone$1,128,004
- Rebecca J. Shaheen$131,956
- Anne Courtney Devries$11,955,219
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAngiogenesisAngiogenesis InhibitionAngiogenesis InhibitorsAntineoplastic AgentsApplications GrantsAttentionBaseBevacizumabBlood Vessel DevelopmentCancer CellCancer EtiologyCancer ModelCancer TypeCell GrowthCell LineCell MotilityCell ProliferationCell TypeCessation Of LifeClinicClinical TrialsColonAdvanced Disease
Grant awards (3)
Development of a novel antiangiogenic drug for colon cancer by targeting neuropeptide Y receptors$90,098
R21 · FY2019 · CA · contact PI
Development of a novel antiangiogenic drug for colon cancer by targeting neuropeptide Y receptors$74,462
R21 · FY2019 · CA · contact PI
Development of a novel antiangiogenic drug for colon cancer by targeting neuropeptide Y receptors$203,363
R21 · FY2018 · CA · contact PI